Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Income towards Parent Company (2023 - 2025)

Historic Income towards Parent Company for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.

  • Compass Therapeutics' Income towards Parent Company fell 2923.44% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 4154.73%. This contributed to the annual value of -$56.6 million for FY2024, which is 3325.41% down from last year.
  • Per Compass Therapeutics' latest filing, its Income towards Parent Company stood at -$15.8 million for Q3 2025, which was down 2923.44% from -$21.1 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Income towards Parent Company peaked at -$7.8 million during Q1 2023, and registered a low of -$21.1 million during Q2 2025.
  • Moreover, its 3-year median value for Income towards Parent Company was -$13.1 million (2024), whereas its average is -$13.5 million.
  • Per our database at Business Quant, Compass Therapeutics' Income towards Parent Company crashed by 1594.25% in 2024 and then plummeted by 6110.43% in 2025.
  • Quarter analysis of 3 years shows Compass Therapeutics' Income towards Parent Company stood at -$13.4 million in 2023, then fell by 23.55% to -$16.6 million in 2024, then increased by 4.57% to -$15.8 million in 2025.
  • Its Income towards Parent Company stands at -$15.8 million for Q3 2025, versus -$21.1 million for Q2 2025 and -$16.6 million for Q1 2025.